ArticleBreast cancer (Dove Medical Press)2026
The Regulatory Mechanism and Value in Early Diagnosis and Prognosis Assessment of miR-4448 in Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Breast cancer (BC) is heterogeneous malignancy and the most common cancer among women globally. It emphasized the continuous need for effective strategies for early diagnosis and treatment. This study aimed to elucidate the regulatory mechanism of miR-4448 in BC and evaluate its value in early diagnosis and prognosis. Patients and Methods: This analysis included 68 patients with BC. The expression levels of miR-4448 and thiamin pyrophosphokinase 1 ( Results: Compared with the healthy controls, the level of TPK1 in the serum of BC patients was elevated, while miR-4448 levels was significantly reduced. MiR-4448 demonstrated substantial diagnostic value for BC. Low miR-4448 expression was associated with poorer survival outcomes. Inhibition of miR-4448 promoted the migration, invasion and proliferation abilities of BC cells. Conclusion: The study identifies miR-4448 as a potential biomarker for the early diagnosis and prognosis of BC. Inhibiting miR-4448 can promote the development of BC by negatively regulating
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.